ESCHOLTZIA - AUBEPINE - PASSIFLORE BIO
Food supplement declared in France, declaration No 2022-1-1511, decision dated 31 January 2022
ESCHOLTZIA - AUBEPINE - PASSIFLORE BIO (GPH DIFFUSION) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). None of the rules we check flags an issue with its declared composition.
- Brand
- GPH DIFFUSION
- Food business operator placing the product on the market
- SAS GPH DIFFUSION
- Status
- Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
- Form
- Comprimé
- Daily dose
- 2 à 3 comprimés par jour
- Directions for use
- 2 à 3 comprimés par jour avec un grand verre d'eau
Declaration 181820, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.
Regulatory points
None of the rules we check applies to the declared ingredients.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Crataegus laevigata (Poir.) DC. | Sommités fleuries | Poudre (de plantes séchées ou broyées) | 500 mg |
| Eschscholzia californica Cham. | Parties aériennes | Poudre (de plantes séchées ou broyées) | 500 mg |
| Passiflora incarnata L. | Parties aériennes | Poudre (de plantes séchées ou broyées) | 500 mg |
Additives
E504
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Tenir hors de portée des enfants. Dans le cadre d'une alimentation équilibrée et variée. Ne pas dépasser la dose journalière recommandée.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Crataegus laevigata (Poir.) DC.
Read the warning, when it applies and the studies cited
Hawthorn
Route of administration: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.
- Eschscholzia californica Cham.
Read the warning, when it applies and the studies cited
CALIFORNIA POPPY - ESCHSCHOLZIA CALIFORNICA
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Other uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Brinker 2010; Mills and Bone 2005).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid taking with alcohol or products that cause drowsiness and/or with analgesic properties (Brinker 2010; Mills and Bone 2005; Hoffmann 2003).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2015; Berardi et al. 2002).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant (Brinker 2010; Blumenthal et al. 2000).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Passiflora incarnata L.
Read the warning, when it applies and the studies cited
PASSIONFLOWER -PASSIFLORA INCARNATA
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- ESCHOLTZIA - AUBEPINE - PASSIFLORE BIO BIO ATLANTIC, declared in 2022 : same declared composition
- ESCHOLTZIA - AUBEPINE - PASSIFLORE BIO 123 GELULES, declared in 2022 : same declared composition
Brand : GPH DIFFUSION
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.